<DOC>
	<DOCNO>NCT00212771</DOCNO>
	<brief_summary>The primary feature schizophrenia schizoaffective disorder positive ( inability think clearly distinguish reality fantasy ) negative symptom ( reduction absence normal behavior emotion ) . Other symptom include reduced ability recall learn information , difficulty problem solve maintain productive employment . Asenapine investigational drug may help correct schizophrenia alter inbalance brain hormone dopamine serotonin . This long-term extension trial test efficacy safety asenapine comparator agent ( olanzapine ) treatment patient schizophrenia .</brief_summary>
	<brief_title>Efficacy Safety Asenapine Using Active Control Subjects With Schizophrenia Schizoaffective Disorder ( 25520 ) ( P05846 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Subject schizophrenia schizoaffective disorder . Must complete 12 month treatment protocol 25517 . Subject must sign write informed consent . Have uncontrolled , unstable , clinically significant medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>